Nanocurcumin: A novel strategy in treating ankylosing spondylitis by modulating Th17 cells frequency and function

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• Ankylosing spondylitis (AS) is a chronic inflammatory disease affecting the axial skeleton.
• T-helper 17 (Th17) cells play a significant role in the pathogenesis of AS.
• Nanocurcumin, an anti-inflammatory compound, shows potential therapeutic benefits for AS patients.

Purpose of the Study:

• To evaluate Th17-related immunological parameters in AS patients.
• To investigate the effect of nanocurcumin on Th17 cell activity and related molecules in AS.
• To explore the potential of nanocurcumin in managing AS.

Main Methods:

• Measurement of Th17 cell frequency and cytokine secretion using flow cytometry and ELISA.
• Quantification of transcription factor mRNA, cytokines, and microRNAs (miRNAs) using real-time PCR.
• Comparison of pre- and post-treatment immunological markers in nanocurcumin-treated AS patients versus placebo.

Main Results:

• AS patients exhibited a higher frequency of Th17 cells.
• Nanocurcumin treatment significantly decreased the mRNA expression of RORγt and IL-17.
• Nanocurcumin also reduced the expression of Th17-associated miRNAs (miR-141, miR-155, miR-200) and improved clinical symptoms.

Conclusions:

• Nanocurcumin demonstrates the potential to regulate Th17 cell activity in AS patients.
• The study provides evidence for nanocurcumin's mechanism of action in AS treatment.
• Nanocurcumin may offer a beneficial therapeutic strategy for managing ankylosing spondylitis.